Infineon Leads DAX Losses after Reports of Chinese AI Chip Breakthrough

Market Analysis

Shares of German semiconductor maker Infineon slid to the bottom of the DAX on Tuesday after market reports from Asia raised fears that a Chinese developer has advanced AI-capable chip designs. Infineon fell 4.6% and ranked as the weakest performer in the benchmark index as investors digested news that the Chinese company CXMT is reportedly developing powerful AI chips a narrative that triggered broad profit-taking across semiconductor stocks in Asia and then Europe.

The rout in chips extended beyond Germany. MDAX names such as Elmos, Aixtron, Süss MicroTec and Siltronic lost between roughly 2.6% and 3.9%, following declines in US markets the previous evening and further weakness across Asian sessions. Market strategist Andreas Lipkow of CMC Markets said that reports of CXMTs progress are prompting massive profit-taking in semiconductor shares in South Korea and other Asian markets, and that the prospect of technological competition from China is renewing doubts about whether the high valuations and profit margins of established chip groups remain justified.

South Korean heavyweights Samsung and SK hynix also moved sharply lower after the headlines, helping push the KOSPI down another 5.5% from earlier losses. Taiwanese chip-related equities fell more steeply as well, underscoring the global nature of investor concern that a credible Chinese entrant could reshape competitive dynamics in AI semiconductors.

Despite the pain in tech, the DAX itself showed resilience in early trading, edging up about 0.4% to 25,370 points after bouncing off its 21-day moving average near 25,320 the previous session. The MDAX lifted around 0.3% to 30,185 points, while the EuroStoxx 50 was broadly unchanged versus the prior close.

Selected Movers and Sector Context

On the positive side, stocks in other sectors delivered notable moves. Bio-pharma developer Formycon surged after saying the US Food and Drug Administration has accepted a filing for a biosimilar, FYB206, which would compete with Merck & Co.s blockbuster cancer drug Keytruda. Formycon shares jumped as much as 13% intraday, reaching the highest level since mid-June before settling with a roughly 10% gain; trading volumes were well above average. Keytruda generated global sales of about $31.7 billion last year, underscoring the commercial importance of any successful biosimilar.

Finnair also gained momentum after raising its full-year guidance. The Finnish carrier said travel demand exceeded expectations and helped offset higher fuel costs. Management now expects annual revenue of €3.53.6 billion (up from €3.43.5 billion previously) and an adjusted operating result in a range of €175220 million versus an earlier forecast of €120190 million. Finnairs shares climbed roughly 14% on the update, with the company noting that some of the higher fuel expenses were passed through via ticket pricing.

Overall, the trading day illustrated two simultaneous market themes: a renewed risk-off in technology and semiconductor names driven by geopolitical and competitive concerns around AI chip design, and selective stock-specific rallies led by positive regulatory or operational news in healthcare and travel.

Investors will likely watch upcoming corporate updates and any follow-up reporting on CXMT closely. If the Chinese development proves substantive, it could force a re-assessment of earnings trajectories and valuation multiples for established chipmakers; if the news is later judged less disruptive, some of the recent underperformance could recover. For now, the market is pricing in heightened uncertainty for the semiconductor complex while allocating gains to individual winners in other sectors.